| scholarly article | Q13442814 |
| P356 | DOI | 10.1517/13543784.2012.665871 |
| P953 | full work available at URL | http://www.informapharmascience.com/doi/abs/10.1517/13543784.2012.665871 |
| http://www.tandfonline.com/doi/pdf/10.1517/13543784.2012.665871 | ||
| P698 | PubMed publication ID | 22394161 |
| P2093 | author name string | Sapna P. Patel | |
| Kevin B. Kim | |||
| P2860 | cites work | Mutations in GNA11 in uveal melanoma | Q24625723 |
| Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation | Q24629474 | ||
| Improved survival with vemurafenib in melanoma with BRAF V600E mutation | Q24631953 | ||
| Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi | Q24646052 | ||
| RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth | Q27659493 | ||
| MEK1 mutations confer resistance to MEK and B-RAF inhibition | Q27777362 | ||
| Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers | Q27851426 | ||
| BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation | Q27851610 | ||
| Mutations of the BRAF gene in human cancer | Q27860760 | ||
| Improved Survival with Ipilimumab in Patients with Metastatic Melanoma | Q27861062 | ||
| Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths | Q28241157 | ||
| Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo | Q28368373 | ||
| BRAF mutation predicts sensitivity to MEK inhibition | Q29614281 | ||
| Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K | Q29614757 | ||
| Distinct sets of genetic alterations in melanoma | Q29614965 | ||
| COT drives resistance to RAF inhibition through MAP kinase pathway reactivation | Q29615032 | ||
| RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF | Q29616828 | ||
| RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) | Q29620033 | ||
| Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma | Q33384029 | ||
| High level of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886) | Q33717222 | ||
| Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma | Q34633455 | ||
| Vertical Targeting of the Phosphatidylinositol-3 Kinase Pathway as a Strategy for Treating Melanoma | Q34682072 | ||
| A pivotal role for ERK in the oncogenic behaviour of malignant melanoma? | Q35069175 | ||
| Genotype-Dependent Sensitivity of Uveal Melanoma Cell Lines to Inhibition of B-Raf, MEK, and Akt Kinases: Rationale for Personalized Therapy | Q35519172 | ||
| A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors | Q35563528 | ||
| Management of cutaneous melanoma | Q35877006 | ||
| Exon capture analysis of G protein-coupled receptors identifies activating mutations in GRM3 in melanoma. | Q36037070 | ||
| STAT3 Mediates Resistance to MEK Inhibitor through MicroRNA miR-17 | Q36083385 | ||
| Therapeutic Strategies for Targeting Ras Proteins | Q39262217 | ||
| A proliferative melanoma cell phenotype is responsive to RAF/MEK inhibition independent of BRAF mutation status | Q39802879 | ||
| Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma | Q39971699 | ||
| Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor | Q40164535 | ||
| Detection of B-RAF and N-RAS mutations in human melanoma | Q40442042 | ||
| Mitogen-activated protein/extracellular signal-regulated kinase kinase inhibition results in biphasic alteration of epidermal homeostasis with keratinocytic apoptosis and pigmentation disorders. | Q42466391 | ||
| Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells | Q42478581 | ||
| The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer | Q43152544 | ||
| A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel | Q46448115 | ||
| The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel | Q46825496 | ||
| Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma | Q53640355 | ||
| BRIM-2: An open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma | Q58024751 | ||
| Unusual Presentation of Large-Cell Poorly Differentiated Neuroendocrine Carcinoma of the Epiglottis | Q84637981 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | selumetinib | Q7448840 |
| metastatic melanoma | Q18975855 | ||
| P304 | page(s) | 531-539 | |
| P577 | publication date | 2012-03-07 | |
| P1433 | published in | Expert Opinion on Investigational Drugs | Q5421208 |
| P1476 | title | Selumetinib (AZD6244; ARRY-142886) in the treatment of metastatic melanoma | |
| P478 | volume | 21 |
| Q34615593 | Complement pathway is frequently altered in endometriosis and endometriosis-associated ovarian cancer |
| Q38123513 | Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions. |
| Q39035993 | Genomewide RNAi screen identifies protein kinase Cb and new members of mitogen-activated protein kinase pathway as regulators of melanoma cell growth and metastasis |
| Q42773490 | High-throughput sequencing of the melanoma genome |
| Q37060963 | Loss of PI(4,5)P2 5-Phosphatase A Contributes to Resistance of Human Melanoma Cells to RAF/MEK Inhibitors. |
| Q28118859 | MiR-92a mediates AZD6244 induced apoptosis and G1-phase arrest of lymphoma cells by targeting Bim |
| Q36337063 | Novel Drugs Targeting the Epidermal Growth Factor Receptor and Its Downstream Pathways in the Treatment of Colorectal Cancer: A Systematic Review |
| Q57156789 | Phase Ib Results of the Rational Combination of Selumetinib and Cyclosporin A in Advanced Solid Tumors with an Expansion Cohort in Metastatic Colorectal Cancer |
| Q38046128 | Robustness of signal transduction pathways |
| Q38098888 | Targeting MAPK pathway in melanoma therapy |
| Q49364393 | The anti-rheumatic drug, leflunomide, synergizes with MEK inhibition to suppress melanoma growth |
Search more.